RPS25P9

Across TCGA pan-cancer cohorts, RPS25P9 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RPS25P9 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RPS25P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS25P9 expression acts as an unfavorable survival marker, although some lineages such as LGG and MESO show a favorable association.

CHOL, DLBC, and LGG are the cancer types where RPS25P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	II,III,IV	0.111	0.785	<.001	63	view →
DLBC	DFS	Tertile	All	0.251	0.858	.001	48	view →
LGG	OS	Median	All	0.519	0.345	<.001	38	view →
MESO	OS	Tertile	II,III,IV	0.441	0.220	.016	26	view →
PAAD	OS	Tertile	All	0.419	0.637	.009	21	view →
LIHC	DFS	Tertile	II,III,IV	0.769	0.379	.004	18	view →
LUAD	OS	Tertile	All	0.545	0.299	.003	18	view →
SKCM	DFS	Tertile	II,III,IV	0.136	0.330	.023	6	view →
UCS	DFS	Median	IV	0.835	0.490	.031	6	view →
READ	OS	Tertile	All	0.823	0.501	.047	4	view →
ESCA	OS	Tertile	All	0.629	1.000	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RPS25P9–CHOL (OS)

Open the CHOL breakdown →